Repeat stereotactic body radiotherapy for oligometastatic disease

Jonas Willmann(University of North Texas), Nicolaus Andratschke(University Hospital of Zurich), Matthias Gückenberger(University of Zurich), Sebastian M. Christ(University of Zurich), Maiwand Ahmadsei(University Hospital of Zurich), Eugenia Vlaskou Badra(University Hospital of Zurich), Selma Adilovic(University of Zurich), Michael Mayinger(University Hospital of Zurich), Stephanie Tanadini‐Lang(University of Zurich)

Radiotherapy and Oncology

April 12, 2023

10.1016/j.radonc.2023.109671

Cited by 12

Related Papers

Characterisation and classification of oligometastatic disease: a European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer consensus recommendation

|The Lancet Oncology|2020|1.1k

Defining oligometastatic disease from a radiation oncology perspective: An ESTRO-ASTRO consensus document

|Radiotherapy and Oncology|2020|646

EANO–ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up of patients with brain metastasis from solid tumours

|Annals of Oncology|2021|577

ESMO consensus conference recommendations on the management of metastatic melanoma: under the auspices of the ESMO Guidelines Committee

|Annals of Oncology|2020|232

Radiographic changes after lung stereotactic ablative radiotherapy (SABR) – Can we distinguish recurrence from fibrosis? A systematic review of the literature

|Radiotherapy and Oncology|2012|230